Across TCGA pan-cancer cohorts, SAMD9 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SAMD9 data layer compared with 24 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SAMD9 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SAMD9 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, LUAD, and PDAC are the cancer types where SAMD9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	All	0.985	0.416	.017	25	view →
LUAD	DFS	Tertile	III,IV	0.916	0.365	.002	21	view →
PDAC	OS	Tertile	IV	0.425	0.973	.024	6	view →
LSCC	OS	Median	All	0.733	0.885	.023	2	view →
GBM	DFS	Quartile	All	0.674	0.820	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: SAMD9 tumor-vs-normal RNA expression · all SAMD9 data types